A detailed history of Nuveen Asset Management, LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 95,056 shares of CHRS stock, worth $70,341. This represents 0.0% of its overall portfolio holdings.

Number of Shares
95,056
Previous 95,056 -0.0%
Holding current value
$70,341
Previous $164,000 40.24%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$2.02 - $3.14 $1.35 Million - $2.09 Million
-666,263 Reduced 87.51%
95,056 $227,000
Q4 2023

Feb 14, 2024

SELL
$1.59 - $3.85 $348,855 - $844,713
-219,406 Reduced 22.37%
761,319 $2.54 Million
Q3 2023

Nov 14, 2023

BUY
$3.74 - $5.45 $2.62 Million - $3.82 Million
700,899 Added 250.48%
980,725 $3.67 Million
Q2 2023

Aug 14, 2023

BUY
$3.79 - $8.3 $394,792 - $864,586
104,167 Added 59.3%
279,826 $1.19 Million
Q1 2023

May 15, 2023

SELL
$5.89 - $10.52 $1.69 Million - $3.02 Million
-286,867 Reduced 62.02%
175,659 $1.2 Million
Q4 2022

Feb 14, 2023

SELL
$5.69 - $10.07 $1.52 Million - $2.69 Million
-266,911 Reduced 36.59%
462,526 $3.66 Million
Q3 2022

Nov 14, 2022

SELL
$7.17 - $13.87 $1.13 Million - $2.19 Million
-158,148 Reduced 17.82%
729,437 $7.01 Million
Q2 2022

Aug 15, 2022

SELL
$5.86 - $13.23 $832,243 - $1.88 Million
-142,021 Reduced 13.79%
887,585 $6.43 Million
Q1 2022

May 16, 2022

BUY
$10.92 - $16.41 $3.53 Million - $5.31 Million
323,408 Added 45.8%
1,029,606 $12.5 Million
Q4 2021

Feb 14, 2022

SELL
$15.81 - $18.99 $280,548 - $336,977
-17,745 Reduced 2.45%
706,198 $11.3 Million
Q3 2021

Nov 12, 2021

SELL
$12.68 - $17.79 $466,471 - $654,458
-36,788 Reduced 4.84%
723,943 $11.6 Million
Q2 2021

Aug 16, 2021

BUY
$12.95 - $15.41 $1.09 Million - $1.29 Million
83,940 Added 12.4%
760,731 $10.5 Million
Q1 2021

May 17, 2021

BUY
$14.42 - $21.39 $230,503 - $341,919
15,985 Added 2.42%
676,791 $9.89 Million
Q4 2020

May 17, 2021

SELL
$16.56 - $18.94 $520,199 - $594,962
-31,413 Reduced 4.54%
660,806 $11.5 Million
Q4 2020

Feb 16, 2021

SELL
$16.56 - $18.94 $7.41 Million - $8.48 Million
-447,652 Reduced 39.27%
692,219 $12 Million
Q3 2020

Nov 16, 2020

SELL
$17.41 - $19.89 $52,299 - $59,749
-3,004 Reduced 0.26%
1,139,871 $20.9 Million
Q2 2020

Aug 14, 2020

SELL
$14.43 - $19.16 $1.46 Million - $1.93 Million
-100,961 Reduced 8.12%
1,142,875 $20.4 Million
Q1 2020

May 14, 2020

SELL
$11.67 - $22.53 $8.14 Million - $15.7 Million
-697,864 Reduced 35.94%
1,243,836 $20.2 Million
Q4 2019

Feb 14, 2020

BUY
$16.33 - $21.37 $1.83 Million - $2.39 Million
111,785 Added 6.11%
1,941,700 $35 Million
Q3 2019

Nov 14, 2019

BUY
$16.3 - $23.37 $10.9 Million - $15.6 Million
667,224 Added 57.39%
1,829,915 $37.1 Million
Q2 2019

Aug 15, 2019

BUY
$13.1 - $22.1 $15.2 Million - $25.7 Million
1,162,691 New
1,162,691 $25.7 Million

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $57.5M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.